Shares shifted as Femasys Inc. (FEMY) jumped 8.8% after hours to $2.79 on September 15, reversing a 4.1% regular-session decline—a swing triggered by news that a Minnesota OB/GYN practice will adopt the company's fertility diagnostic and treatment tools across all four of its locations. For a micro-cap firm with trailing revenue of just $2.37 million, every new customer announcement doubles as a proof-of-concept test for Wall Street.
A Pattern of Small Partnership Wins Is Building, but Revenue Hasn't Kept Pace
Minnesota Women's Care will implement Femasys's ultrasound-based fertility diagnostic and its in-office insemination treatment across all four practice locations. This follows a partnership with UNC Health announced in August to introduce the same products within UNC's statewide OB/GYN locations. The cadence is encouraging, yet sales for the first half of 2026 totaled just $756,716, up a mere 0.8% from the same period in 2025. The gap between press releases and the revenue line remains wide.
A $30 Million Cash Infusion Bought Time—and Dilution
Femasys closed a $30 million private placement in August led by Nantahala Capital with participation from Rosalind Advisors and management. That capital is earmarked for the U.S. sales push and clinical trials for a non-surgical birth control product. But the deal included 9.4 million new shares plus warrants for another 18.75 million shares, creating significant dilution overhang.
Milestone warrants require at least $1.5 million in quarterly U.S. revenue before they can be exercised —a threshold the company has never hit.
The Product Works in Trials, but Commercial Proof Is Still Early
In its pivotal trial, the insemination treatment achieved more than double the pregnancy rates of the traditional method in cases of low male sperm count.
An estimated 10 million U.S. women face infertility, yet fewer than 1% receive care at specialized fertility centers —a gap Femasys aims to fill by equipping regular gynecologists. The company only recorded its first revenue-generating commercial use in May 2026.
The Bottom Line for Investors
Femasys executed a 1-for-20 reverse stock split in June to stay listed on Nasdaq—a move that rarely inspires confidence. Four analysts rate the stock a "Strong Buy" with a $5.50 target , but with a $2.37 million revenue base and -$3.6 million net loss in H1 alone, market-implied metrics indicate a substantially elevated probability of financial distress. The Minnesota deal is a positive signal, not a turning point.